The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer's disease

Neural Plasticity

Volumn 12, Issue 4, 2005, Pages 311-328

  Messier, Claude ^a   Teutenberg, Kevin ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cognitive function; Dementia; Diabetes; Glucose regulation; Hyperinsulinemia; Impaired glucose tolerance; Literature review; Memory; Vascular disease

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; GLUCOSE; INSULIN; INSULIN RECEPTOR; INSULINASE; SOMATOMEDIN C;

AGING; ALZHEIMER DISEASE; ATTENTION; BIOACCUMULATION; BLOOD BRAIN BARRIER; BRAIN ELECTROPHYSIOLOGY; BRAIN FUNCTION; BRAIN METABOLISM; CLINICAL TRIAL; COGNITION; DATA ANALYSIS; DISEASE ASSOCIATION; EVOKED RESPONSE; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MEMORY; NERVE CELL PLASTICITY; NERVOUS SYSTEM PARAMETERS; NEUROMODULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS; REGULATORY MECHANISM; REVIEW;

AGING; ALZHEIMER DISEASE; AMYLOID; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; COGNITION; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; INSULYSIN; SOMATOMEDINS;

EID: 30444447214     PISSN: 20905904     EISSN: None     Source Type: Journal    
DOI: 10.1155/NP.2005.311     Document Type: Review

References (126)

1. Abbott MA, Wells DG, Fallon JR. 1999. The insulin receptor tyrosine kinase substrate p58/53 and the insulin receptor are components of CNS synapses. J Neurosci 19: 7300-7308.
2. Abraham R, Myers A, Wavrant-DeVrieze F, Hamshere ML, Thomas HV, Marshall H, et al. 2001. Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease. Hum Genet 109: 646-652.
3. Ahmadian G, Ju W, Liu L, Wyszynski M, Lee SH, Dunah AW, et al. 2004. Tyrosine phosphorylation of GluR2 is required for insulin-stimulated AMPA receptor endocytosis and LTD. Embo J 23: 1040-1050.
4. Anand Kumar TC, David GFX, Umberkoman B, Saini KD. 1974. Uptake of radioactivity by body fluids and tissues in rhesus monkeys after intravenous injection or intranasal spray of tritium-labelled estradiol and progesterone. Curr Sci 1974. 43: 435-439.
5. Araki Y, Nomura M, Tanaka H, Yamamoto H, Yamamoto T, Tsukaguchi I, et al. 1994. MRI of the brain in diabetes mellitus. Neuroradiology 36: 101-103.
6. Awad N, Gagnon M, Messier C. 2004. The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol 26: 1044-1080.
7. Baker LD, Watson GS, Cholerton B, Reger MA, Chapman D, Hyde K, et al. 2003. Acute Intranasal Insulin Administration Improves Verbal Memory for Adults With Alzheimer's Disease. Society for Neuroscience Meeting.
8. Banks WA. 2004. The source of cerebral insulin. Eur J Pharmacol 490: 5-12.
9. Banks WA, Jaspan JB, Huang W, Kastin AJ. 1977a. Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin. Peptides 18: 1423-1429.
10. Banks WA, Jaspan JB, Kastin AJ. 1997b. Effect of diabetes mellitus on the permeability of the blood-brain barrier to insulin. Peptides 18: 1577-1584.
11. Banks WA, Jaspan JB, Kastin AJ. 1997c. Selective physiological transport of insulin across the blood-brain barrier: novel demonstration by species-specific radioimmunoassays. Peptides 18: 1257-62.
12. Banks WA, Kastin AJ, Pan W. 1999. Uptake and degradation of blood-borne insulin by the olfactory bulb. Peptides 20: 373-8.
13. Baskin DG, Figlewicz DP, Woods SC, Porte D Jr, Dorsa DM. 1987. Insulin in the brain. Annu Rev Physiol 49: 335-347.
14. Baskin DG, Stein LJ, Ikeda H, Woods SC, Figlewicz DP, Porte D Jr, et al. 1985. Genetically obese Zucker rats have abnormally low brain insulin content. Life Sci 36: 627-633.
15. Baxter RC, Binoux MA, Clemmons DR, Conover CA, Drop SL, Holly JM, et al. 1998. Recommendations for nomenclature of the insulin-like growth factor binding protein superfamily. J Clin Endocrinol Metab 83: 3213. also Endocrinology 139: 4036.
16. Beck KD, Powell-Braxton L, Widmer HR, Valverde J, Hefti F. 1995. Igf1 gene disruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatal parvalbumin-containing neurons. Neuron 14: 717-730.
17. Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, et al. 2004. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29: 1326-1334.
18. Bereket A, Lang CH, Blethen SL, Ng LC, Wilson TA. 1996. Insulin treatment normalizes reduced free insulin-like growth factor-I concentrations in diabetic children. Clin Endocrinol (Oxf) 45: 321-326.
19. Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S, et al. 2000. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 290(5500): 2302-2303.
20. Biessels GJ, van der Heide LP, Kamal A, Bleys RL, Gispen WH. 2002. Ageing and diabetes: implications for brain function. Eur J Pharmacol 441: 1-14.
21. Bingham EM, Hopkins D, Smith D, Pernet A, Hallett W, Reed L, et al. 2002. The role of insulin in human brain glucose metabolism: an 18fluorodeoxyglucose positron emission tomography study. Diabetes 51: 3384-3390.
22. Blanchard JG, Duncan, PM. 1997. Effect of combinations of insulin, glucose and scopolamine on radial arm maze performance. Pharmacol Biochem Behav 58: 209-214.
23. Blomqvist ME, Chalmers K, Andreasen N, Bogdanovic N, Wilcock GK, Cairns NJ, et al. 2005. Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain. Neurobiol Aging 26: 795-802.
24. Bondy CA, Cheng, CM. 2004. Signaling by insulin-like growth factor 1 in brain. Eur J Pharmacol 490: 25-31.
25. Boussaha M, Hannequin D, Verpillat P, Brice A, Frebourg T, Campion D. 2002. Polymorphisms of insulin degrading enzyme gene are not associated with Alzheimer's disease. Neurosci Lett 329: 121-123.
26. Brayne C, Gill C, Huppert FA, Barkley C, Gehlhaar E, Girling DM, et al. 1998. Vascular risks and incident dementia: results from a cohort study of the very old. Dement Geriatr Cogn Disord 9: 175-180.
27. Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, et al. 2000. Role of brain insulin receptor in control of body weight and reproduction. Science 289(5487): 2122-2125.
28. Bucht G, Adolfsson R, Lithner F, Winblad B. 1983. Changes in blood glucose and insulin secretion in patients with senile dementia of Alzheimer type. Acta Med Scand 213: 387-392.
29. Caccamo A, Oddo S, Sugarman MC, Akbari Y, La Ferla FM. 2005. Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders Neurobiol Aging 26: 645-654.
30. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I. 2002. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 8: 1390-1397.
31. Carson MJ, Behringer RR, Brinster RL, McMorris FA. 1993. Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice. Neuron 10: 729-740.
32. Clemmons DR. 2004. Role of insulin-like growth factor in maintaining normal glucose homeostasis. Horm Res 62 Suppl 1: 77-82.
33. Convit A, Wolf OT, Tarshish C, de Leon MJ. 2003. Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc Natl Acad Sci USA. 100: 2019-2022.
34. Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA, et al. 2003 Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 162: 313-319.
35. Craft S, Asthana S, Cook DG, Baker LD, Cherrier M, Purganan K, et al. 2003. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 28: 809-822.
36. Craft S, Asthana S, Schellenberg G, Baker L, Cherrier M, Boyt AA, et al. 2000. Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann NY Acad Sci 903: 222-228.
37. Craft S, Dagogo-Jack SE, Wiethop BV, Murphy C, Nevins RT, Fleischman S, et al. 1993. Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. Behav Neurosci 107: 926-940.
38. Craft S, Newcomer J, Kanne S, Dagogo-Jack S, Cryer P, Sheline Y, et al. 1996. Memory improvement following induced hyperinsulinemia in Alzheimer's Disease. Neurobiol Aging 17: 123-130.
39. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D Jr. 1998. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 50: 164-168.
40. Curb JD, Rodriguez BL, Abbott RD, Petrovitch H, Ross GW, Masaki KH, et al. 1999. Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology 52: 971-915.
41. D'Ercole AJ, Ye P, O'Kusky, JR. 2002. Mutant mouse models of insulin-like growth factor actions in the central nervous system. Neuropeptides 36: 209-220.
42. den Heijer T, Vermeer SE, van Dijk EJ, Prins ND, Koudstaal PJ, Hofman A, et al. 2003. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 46: 1604-1610.
43. Devaskar SU, Giddings SJ, Rajakumar PA, Carnaghi LR, Menon RK, Zahm DS. 1994. Insulin gene expression and insulin synthesis in mammalian neuronal cells. J Biol Chem 269: 8445-8454.
44. Dore S, Kar S, Rowe W, Quirion R. 1997. Distribution and levels of [125I]IGF-I, [125I]IGF-II and [125I]insulin receptor binding sites in the hippocampus of aged memory-unimpaired and -impaired rats. Neuroscience 80: 1033-1040.
45. Ertekin-Taner N, Allen M, Fadale D, Scanlin L, Younkin L, Petersen RC, et al. 2004. Genetic variants in a haplotype block spanning IDE are significantly associated with plasma Abeta42 levels and risk for Alzheimer disease. Hum Mutat 23: 334-342.
46. Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Baker M, Adamson J, et al., 2000. Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science 290(5500): 2303-2304.
47. Farris W, Leissring MA, Hemming ML, Chang AY, Selkoe DJ. 2005 Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein. Biochemistry 4417: 6513-6525.
48. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, et al. 2003. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 100: 4162-4167.
49. Fontbonne A, Berr C, Ducimetiere P, Alperovitch A. 2001. Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study. Diabetes Care 24: 366-370.
50. Frey W. 2002. Intranasal delivery: bypassing the blood-brain barrier to deliver therapeutic agents to the brain and spinal cord. Drug Deliv Technol 2: 46-49.
51. Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, et al. 1998. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 105: 423-438.
52. Frystyk J, Skjaerbaek C, Vestbo E, Fisker S, Orskov H. 1999. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev 15: 314-322.
53. Fujisawa Y, Sasaki K, Akiyama K. 1991 Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type. Biol Psychiatry 30: 1219-1228.
54. Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, et al. 2001. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 21: 2561-2570.
55. Gerozissis K. 2003. Brain insulin: regulation, mechanisms of action and functions. Cell Mol Neurobiol 23: 1-25.
56. Gerozissis K, Rouch C, Lemierre S, Nicolaidis S, Orosco M. 2001. A potential role of central insulin in learning and memory related to feeding. Cell Mol Neurobiol 21: 389-401.
57. Gizurarson S, Sigurdsson P, Thorvaldsson T, Gunnarsson E 1995. Technique for administering drugs to the brain and bypassing the blood-brain-barrier. Scand J Lab Anim Sci 22: 273-276.
58. Gonzalez C, Martin T, Cacho J, Brenas MT, Arroyo T, Garcia-Berrocal B, et al. 1999. Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers. Eur J Clin Invest 29: 637-642.
59. Gopinath PG, Gopinath G, Kumar TC. 1978. A Target site of intranasally sprayed substances and their transport across the nasal mucosa: a new insight into the intranasal route of drug-delivery. Curr Ther Res 23: 596-607.
60. Gregg EW, Yaffe K, Cauley JA, Rolka DB, Blackwell TL, Narayan KM, Cummings SR. 2000. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med 160: 174-180.
61. Heitner J, Dickson D. 1997. Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study. Neurology 49: 1306-1311.
62. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z. et al., 2004. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18: 902-904.
63. Hsieh J, Aimone JB, Kaspar BK, Kuwabara T, Nakashima K, Gage FH. 2004. IGF-I instructs multipotent adult neural progenitor cells to become oligodendrocytes. J Cell Biol. 164: 111-122.
64. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, et al. 2000. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to bio-chemical and pathological deposition. Nat Med 6: 143-150.
65. Jain S, Golde DW, Bailey R, Geffner ME. 1998. Insulin-like growth factor-I resistance. Endocr Rev 19: 625-646.
66. Juul A. 2003. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 13: 113-170.
67. Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE. 1994. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol (Oxf) 41: 85-93.
68. Kaiyala KJ, Prigeon RL, Kahn SE, Woods SC, Schwartz MW. 2000. Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes 49: 1525-1533.
69. Kern W, Born J, Schreiber H, Fehm HL. 1999. Central nervous system effects of intranasally administered insulin during euglycemia in men. Diabetes 48: 557-563.
70. Kern W, Lieb K, Kerner W, Born J, Fehm HL. 1990. Differential effects of human and pork insulin-induced hypoglycemia on neuronal functions in humans. Diabetes 39: 1091-1098.
71. Kern W, Peters A, Fruehwald-Schultes B, Deininger E, Born J, Fehm HL. 2001. Improving influence of insulin on cognitive functions in humans. Neuroendocrinology 74: 270-280.
72. Kern W, Peters A, Born J, Fehm HL. 1998. Effects of hyperinsulinemia on sensory processing during an euglycemic clamp in healthy subjects. Exp Clin Endocrinol Diabetes 106: A15-A16. [abstract]
73. Kilander L, Boberg M, Lithell H. 1993. Peripheral glucose metabolism and insulin sensitivity in Alzheimer's disease. Acta Neurol Scand. 87: 294-298.
74. Kopf SR, Baratti CM. 1995. The impairment of retention induced by insulin in mice may be mediated by a reduction in central cholinergic activity. Neurobiol Learn Mem 63: 220-228.
75. Kopf SR, Baratti CM. 1999. Effects of posttraining administration of insulin on retention of a habituation response in mice: participation of a central cholinergic mechanism. Neurobiol Learn Mem 71: 50-61.
76. Kupila A, Sipila J, Keskinen P, Simell T, Knip M, Pulkki K, et al. 2003. Intranasally administered insulin intended for prevention of type 1 diabetes - a safety study in healthy adults. Diabetes Melab Res Rev 19: 415-420.
77. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, et al. 1997. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 145: 301-308.
78. Ling X, Martins RN, Racchi M, Craft S, Helmerhorst E. 2002. Amyloid beta antagonizes insulin promoted secretion of the amyloid beta protein precursor. J Alzheimers Dis 4: 369-374.
79. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. 2001. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol. 154: 635-641.
80. Messier C. 2003. Diabetes, Alzheimer's disease and apolipoprotein genotype. Exp Gerontol 38: 941-946.
81. Messier C, Awad N, Gagnon M. 2004. The relationships between atherosclerosis, heart disease, type 2 diabetes and dementia. Neurol Res 26: 567-572.
82. Messier C, Destrade C. 1994. Insulin attenuates scopolamine-induced memory deficits. Psychobiology 22: 16-21.
83. Messier C, White NM. 1987. Memory improvement by glucose, fructose, and two glucose analogs: a possible effect on peripheral glucose transport. Behav Neural Biol 48: 104-127.
84. Mielke JG, Taghibiglou C, Liu L, Zhang Y, Jia Z, Adeli K, et al. 2005. A biochemical and functional characterization of diet-induced brain insulin resistance. J Neurochem 93: 1568.
85. Mustafa A, Lannfelt L, Lilius L, Islam A, Winblad B, Adem A. 1999. Decreased plasma insulin-like growth factor-I level in familial Alzheimer's disease patients carrying the Swedish APP 670/671 mutation. Dement Geriatr Cogn Disord 10: 446-451.
86. Niikura T, Hashimoto Y, Okamoto T, Abe Y, Yasukawa T, Kawasumi M, et al. 2001. Insulin-like growth factor I (IGF-I) protects cells from apoptosis by Alzheimer's V642I mutant amyloid precursor protein through IGF-I receptor in an IGF-binding protein-sensitive manner. J Neurosci. 21: 1902-1910.
87. O'Kusky JR, Ye P, D'Ercole AJ. 2000. Insulin-like growth factor-I promotes neurogenesis and synaptogenesis in the hippocampal dentate gyrus during postnatal development. J Neurosci 2000. 20: 8435-8442.
88. O'Kusky JR, Ye P, D'Ercole AJ. 2003. Increased expression of insulin-like growth factor I augments the progressive phase of synaptogenesis without preventing synapse elimination in the hypoglossal nucleus. J Comp Neurol 464: 382-391.
89. Obici S, Feng Z, Karkanias G, Baskin DG, Rossetti L. 2002. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat Neurosci 56: 566-572.
90. Orosco M, Gerozissis K, Rouch C, Nicolaidis S. 1995. Feeding-related immunoreactive insulin changes in the PVN-VMH revealed by microdialysis. Brain Res 671: 149-158.
91. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MM. 1996. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 39: 1392-1397.
92. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. 1999. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53: 1937-1942.
93. Palovcik RA, Phillips MI, Kappy MS, Raizada MK. 1984. Insulin inhibits pyramidal neurons in hippocampal slices. Brain Res 309: 187-191.
94. Pardridge WM, Kang YS, Buciak JL, Yang J. 1995. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm Res 12: 807-816.
95. Park, CR; Seeley, RJ; Woods, SC. 1995. ICV insulin increases performance on a passive avoidance task. Soc Neurosci Abstracts 21: 949.
96. Paulus K, Schulz C, Lehnert, H. 2005. Central nervous effects of leptin and insulin on hippocampal leptin and insulin receptor expression following a learning task in Wistar rats. Neuropsychobiology 51: 100-106.
97. Peila R, Rodriguez BL, Launer U. 2002. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies - The Honolulu-Asia Aging Study. Diabetes 51: 1256-1262.
98. Phiel CJ, Wilson CA, Lee VM, Klein PS. 2003. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423(6938): 435-439.
99. Poduslo, JF, Curran, GL, Wengenack, TM, Malester, B and Duff, K 2001. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8: 555-567.
100. Popken GJ, Hodge RD, Ye P, Zhang J, Ng W, O'Kusky JR, D'Ercole AJ, et al. 2004. In vivo effects of insulin-like growth factor-I (IGF-I) on prenatal and early postnatal development of the central nervous system. Eur J Neurosci 198: 2056-2068.
101. Porte D Jr, Baskin DG, Schwartz MW. 2005. Insulin signaling in the central nervous system: a critical role in metabolic homeostasis and disease from C. elegans to humans. Diabetes 545: 1264-1276.
102. Prince JA, Feuk L, Gu HF, Johansson B, Gatz M, Blennow K, et al. 2003. Genetic variation in a haplotype block spanning IDE influences Alzheimer disease. Hum Mutat 22: 363-371.
103. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, et al. 2000. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7: 321-331.
104. Rollero A, Murialdo G, Fonzi S, Garrone S, Gianelli MV, Gazzerro E, et al. 1998. Relationship between cognitive function, growth hormone and insulin-like growth factor I plasma levels in aged subjects. Neuropsychobiology 38: 73-79.
105. Rotwein P, Burgess SK, Milbrandt JD, Krause JE. 1998. Differential expression of insulin-like growth factor genes in rat central nervous system. Proc Natl Acad Sci USA 85: 265-269.
106. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ. 2002. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 359(9319): 1740-1745.
107. Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, et al. 2004. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci USA 101: 3100-3105.
108. Schulingkamp RJ, Pagano TC, Hung D, Raffa RB. 2000. Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci Biobehav Rev 24: 855-872.
109. Schwartz MW, Porte D Jr. 2005. Diabetes, obesity, and the brain. Science 307(5708): 375-379.
110. Selkoe DJ. 2001. Clearing the brain's amyloid cobwebs. Neuron 32: 177-180.
111. Shiiki T, Ohtsuki S, Kurihara A, Naganuma H, Nishimura K, Tachikawa M, et al. 2004. Brain insulin impairs amyloid-beta(1-40) clearance from the brain. J Neurosci 24: 9632-9637.
112. Soininen H, Puranen M, Helkala EL, Laakso M, Riekkinen PJ. 1992. Diabetes mellitus and brain atrophy: a computed tomography study in an elderly population. Neurobiol Aging 13: 717-721.
113. Spreen O, Strauss E. 1998. A Compendium of Neuropsychological Tests. New York, NY, USA, Oxford University Press.
114. Strachan MW, Deary IJ, Ewing FM, Frier BM. 1997. Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 20: 438-445.
115. Tamburrano G, Lala A, Locuratolo N, Leonetti F, Sbraccia P, Giaccari A, et al., 1988. Electro-encephalography and visually evoked potentials during moderate hypoglycemia. J Clin Endocrinol Metab 66: 1301-1306.
116. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd. 2004. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127: 481-496.
117. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, et al. 2000. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci 20: 1657-1665.
118. Wan Q, Xiong ZG, Man HY, Ackerley CA, Braunton J, Lu WY, et al. 1997. Recruitment of functional GABA(A) receptors to postsynaptic domains by insulin. Nature 388(6643):686-690.
119. Watson GS, Peskind ER, Asthana S, Purganan K, Wait C, Chapman D, et al. 2003. Insulin increases CSF Abeta42 levels in normal older adults. Neurology 60: 1899-1903.
120. Wechsler D. 1981. Wechsler Adult Intelligence Scale-Revised. New York, NY, USA: Harcourt Brace Jovanovich.
121. Werther GA, Abate M, Hogg A, Cheesman H, Oldfield B, Hards D, et al. 1990. Localization of insulin-like growth factor-I mRNA in rat brain by in situ hybridization - relationship to IGF-I receptors. Mol Endocrinol. 1990 May;4(5): 773-778.
122. Woods SC, Seeley RJ, Baskin DG, Schwartz MW. 2003. Insulin and the blood-brain barrier. Curr Pharm Des 9: 795-800.
123. Xie L, Helmerhorst E, Taddei K, Plewright B, Van Bronswijk W, Martins R. 2002. Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 22: RC221
124. Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, Ubeda OJ, et al. 2004. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci 24: 11120-11126.
125. Zhao W, Chen H, Xu H, Moore E, Meiri N, Quon MJ, et al., 1999. Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J Biol Chem 274: 34893-34902.
126. Zhong J, Deng J, Phan J, Dlouhy S, Wu H, Yao W, et al. 2005. Insulin-like growth factor-I protects granule neurons from apoptosis and improves ataxia in weaver mice. J Neurosci Res 80: 481-990.